Professor of Neurology and the Walter Bradley Chair in ALS Research at the University of Miami Miller School of Medicine. A trailblazer in pre-symptomatic ALS research, Professor Benatar has led international consortia to discover early biomarkers and develop preventative strategies for amyotrophic lateral sclerosis.
Professor of Neurology at University College London, Director of the UCL Huntington’s Disease Centre, and Group Leader at the UK Dementia Research Institute. Professor Tabrizi spearheaded the first-in-human gene-lowering trials for Huntington’s disease, identifying key biomarkers and translational pathways for neurodegeneration.
Professor of Molecular Therapeutics at the University of California, Berkeley, and Director at the Innovative Genomics Institute. A pioneer in genome editing, Professor Urnov co-developed foundational CRISPR/Cas tools and, as a co-founder of the CRISPR Cures centre, helped shepherd the development of a bespoke CRISPR base-editing therapy for “Baby KJ”, the first-ever personalized in vivo gene … Read more
Institute Professor in the Departments of Chemical and Biomedical Engineering at MIT, and faculty member of the Harvard–MIT Program in Health Sciences and Technology and the Koch Institute for Integrative Cancer Research. A pioneer in controlled drug delivery, Langer holds over 1,400 patents and has authored over 1,600 papers. He advises Evox on brain and … Read more
Professor of Neuroscience and Deputy Head of the Medical Sciences Division at the University of Oxford, and Director of the Laboratory of RNA Biology and Neuromuscular Disease. He launched the field of exosome therapeutics by bioengineering exosomes for RNA delivery in the brain, demonstrating their potential as natural nanocarriers for CNS applications
Professor of Biomolecular Medicine and Advanced Therapy at Karolinska Institutet, where he leads the exosome research group within the Department of Laboratory Medicine Karolinska Institutet. A pioneer in extracellular vesicle–based drug delivery, Professor El Andaloussi has characterised exosome biology and engineered novel exosome platforms for macromolecule-based therapies targeting neurodegenerative and neuromuscular diseases